MedTrace Logo

Pharmacokinetics of the Basel Phenotyping Cocktail Combination Capsule

NCT03247699 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 12

Last updated 2017-09-21

No results posted yet for this study

Summary

Healthy Subjects will receive treatment orally with 120-200ml tap water in fasted state.

Treatment in period A is the "Basel phenotyping cocktail" capsule. Treatment in period B consists of simultaneous intake of isolated formulations. In both study arms peripheral venous and capillary blood (DBS) samples will be drawn

Conditions

  • CYP450 Phenotyping

Interventions

OTHER

"Basel phenotyping cocktail" capsule

Oral intake of "Basel phenotyping cocktail" capsule and pharmacokinetics (PK) sampling

OTHER

"Basel phenotyping cocktail" individual components

Oral intake of "Basel phenotyping cocktail" individual components and PK sampling

Sponsors & Collaborators

  • University Hospital, Basel, Switzerland

    lead OTHER

Principal Investigators

  • Stephan Krähenbühl, MD PhD · Universitätsspital Basel, Switzerland

Study Design

Allocation
RANDOMIZED
Purpose
OTHER
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
50 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2017-06-12
Primary Completion
2017-07-01
Completion
2017-07-30

Countries

  • Switzerland

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03247699 on ClinicalTrials.gov